Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Otsuka
Pharma
Celltrion buy, Rexulti CRL, Glenmark-Hengrui—Fierce Pharma Asia
Celltrion bought a Lilly plant in the U.S. The FDA turned down Lundbeck and Otsuka's PTSD application. Hengrui and Glenmark signed an ADC deal.
Angus Liu
Sep 26, 2025 10:00am
Moderna, Otsuka-Lundbeck, Pfizer-3SBio—Fierce Pharma Asia
Jul 25, 2025 9:46am
FDA advisors overwhelmingly reject Lundbeck, Otsuka's PTSD drug
Jul 21, 2025 11:34am
FDA questions Rexulti efficacy in PTSD after failed phase 3
Jul 16, 2025 2:38pm
RemeGen, Harbour, Datroway—Fierce Pharma Asia
Jun 27, 2025 8:37am
Pfizer CEO, Otsuka, Novartis-MSN—Fierce Pharma Asia
Jun 13, 2025 9:18am
